Category GH Axis

Ipamorelin: The Complete Guide

Ipamorelin's reputation rests on real selectivity data — but its only completed human trial tested gut motility, not growth hormone, and it failed. This guide covers the actual evidence gap, why it's almost always paired with CJC-1295, and the practical dosing math for this widely-used but thinly-studied compound.

CJC-1295: The Complete Guide

CJC-1295 comes in two versions that work completely differently — and confusing them changes what you're actually researching. This guide covers the real DAC versus no-DAC distinction, the 2006 human trial that doesn't match current use, a named FDA safety signal, and the practical dosing math for this widely-used compound.

Tesamorelin: The Complete Guide

Tesamorelin stands apart from every other GH-axis compound in this guide series — it's the only one with genuine FDA approval and a completed Phase 3 program behind it. This guide covers its real clinical evidence, the documented HbA1c safety signal, and how it compares to CJC-1295 and Ipamorelin's far thinner trial history.

IGF-1LR3: The Complete Guide

IGF-1 LR3 works downstream of GH secretagogues like CJC-1295 — activating the same receptor those compounds aim to boost signal to. This guide covers its real mechanism, why it needs acetic acid instead of standard BAC water, a genuine blood sugar risk with a concrete action plan, and why no human trial supports its actual use case.

CJC-1295 & Ipamorelin: The Complete Guide

CJC-1295 and Ipamorelin activate two separate receptor pathways that converge on the same pituitary cells — using them together isn't just convention, it's where the pharmacology actually points. This guide covers the DAC-version distinction that matters most when sourcing this blend, the real evidence gap behind both compounds, and the practical dosing math.